Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login

Report this comment to a moderator

Please fill in the form below if you think a comment is unsuitable. Please indicate which comment is of concern and why. Your comments will be sent to our moderator for review.

Report comment to moderator

MandatoryRequired fields.


Relocation of the EMA: implications for medicines regulation


Sadly, a shocking state of affairs with no winners. Unfortunately, the biggest loser will be the public at least in the short to medium term while the relocated EMA gets up to speed. Plenty of resources that could have been used to improve healthcare in the EU will be wasted in the move. In the long run, the UK will probably sustain the biggest loss at many levels. This loss is unlikely to be reversible and will have profound and unfavourable long-term consequences for medicines regulation in the UK. It will also undermine the UKs position as a premier regulator in Europe.

Posted date

27 OCT 2017

Posted time



Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.